Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Shares Acquired by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC lifted its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 11.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,636 shares of the biopharmaceutical company’s stock after purchasing an additional 2,477 shares during the period. Stephens Investment Management Group LLC’s holdings in Alexion Pharmaceuticals were worth $3,096,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. FMR LLC lifted its holdings in Alexion Pharmaceuticals by 10.4% in the first quarter. FMR LLC now owns 29,144,320 shares of the biopharmaceutical company’s stock valued at $3,939,729,000 after acquiring an additional 2,746,055 shares during the last quarter. Jennison Associates LLC lifted its holdings in Alexion Pharmaceuticals by 17.3% in the first quarter. Jennison Associates LLC now owns 10,241,457 shares of the biopharmaceutical company’s stock valued at $1,384,440,000 after acquiring an additional 1,512,545 shares during the last quarter. Clearbridge Investments LLC lifted its holdings in Alexion Pharmaceuticals by 12.9% in the first quarter. Clearbridge Investments LLC now owns 5,810,033 shares of the biopharmaceutical company’s stock valued at $785,400,000 after acquiring an additional 665,574 shares during the last quarter. Artisan Partners Limited Partnership lifted its holdings in Alexion Pharmaceuticals by 220.9% in the first quarter. Artisan Partners Limited Partnership now owns 4,248,248 shares of the biopharmaceutical company’s stock valued at $574,278,000 after acquiring an additional 2,924,550 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in Alexion Pharmaceuticals by 2.0% in the first quarter. Northern Trust Corp now owns 2,961,031 shares of the biopharmaceutical company’s stock valued at $400,272,000 after acquiring an additional 58,998 shares during the last quarter. Institutional investors and hedge funds own 93.77% of the company’s stock.

In other news, Director Bros. Advisors Lp Baker sold 300,000 shares of the stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $123.74, for a total transaction of $37,122,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Aradhana Sarin sold 578 shares of the stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $132.00, for a total transaction of $76,296.00. Following the sale, the insider now owns 30,201 shares of the company’s stock, valued at approximately $3,986,532. The disclosure for this sale can be found here. Insiders have sold 428,567 shares of company stock valued at $53,420,869 in the last quarter. Insiders own 4.08% of the company’s stock.



A number of research analysts recently commented on the company. Citigroup decreased their price objective on Alexion Pharmaceuticals from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Thursday, May 23rd. Goldman Sachs Group reissued a “neutral” rating and issued a $142.00 target price on shares of Alexion Pharmaceuticals in a research report on Thursday, May 23rd. BidaskClub raised Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday. ValuEngine lowered Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 8th. Finally, Wedbush initiated coverage on Alexion Pharmaceuticals in a research report on Wednesday, May 22nd. They issued an “outperform” rating and a $173.00 target price on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $162.88.

Shares of ALXN traded up $1.81 during mid-day trading on Friday, hitting $110.85. 1,227,200 shares of the company’s stock were exchanged, compared to its average volume of 2,275,943. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $92.56 and a fifty-two week high of $141.86. The firm has a market capitalization of $24.14 billion, a P/E ratio of 15.63, a P/E/G ratio of 1.03 and a beta of 1.65. The business’s 50 day moving average is $119.38 and its two-hundred day moving average is $126.84. The company has a current ratio of 4.04, a quick ratio of 3.56 and a debt-to-equity ratio of 0.26.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share for the quarter, topping the consensus estimate of $2.13 by $0.51. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. The business had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same quarter in the prior year, the firm earned $2.07 earnings per share. The business’s quarterly revenue was up 15.1% compared to the same quarter last year. On average, equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post 9 earnings per share for the current year.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Story: Market Timing – The Benefits and the Danger

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.